Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CytomX Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
15
71.6
59.5
26.9
68.4
37.3
53.2
101
138
76.2
Research and development
54.8
92.3
104
132
113
114
112
77.7
83.4
68.7
General and administrative
19.9
25.6
33.5
36.8
36
39.2
42.8
30
29.7
29.8
Operating expenses
74.6
118
137
168
149
153
154
108
113
98.6
Operating income
-59.6
-46.3
-77.9
-141
-80.5
-116
-101
-6.48
25
-22.4
Interest expense
1.69
Interest income
0.74
2.67
7.64
8.37
1.84
0.26
1.68
9.84
7.14
5.21
Other non-operating income
-0.07
-0.03
-0.07
-0.14
-0.03
-0.08
0.34
-0.03
-0.04
0.03
Pre-tax income
-58.9
-43.6
-70.3
-133
-78.7
-116
-99.3
3.32
32.1
-17.1
Income tax
-0.02
-0.51
14.3
-0.43
-13.9
0
0
3.89
0.22
0.24
Net income
-58.9
-43.1
-84.6
-133
-64.8
-116
-99.3
-0.57
31.9
-17.4
EBITDA
-57.9
-44.6
-76
-139
-78.1
-113
-99
-4.48
26.6
-21.2
EPS, basic
-1.63
-1.16
EPS, diluted
-1.63
-1.16
Shares, basic (weighted)
36.2
37.2
41.7
45.3
46.1
64.1
65.7
73.8
84.4
138
Shares, diluted (weighted)
36.2
37.2
41.7
45.3
46.1
64.1
65.7
73.8
84.7
138
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
105
178
248
188
192
206
194
17.2
38.1
12.7
Short-term investments
197
189
108
124
99.7
0
157
62.6
124
Receivables
2.16
10.1
0.1
0.01
0.8
0.79
36
3.43
3.1
2.01
Other current assets
3.9
4.35
9.25
7.18
7.1
4.29
7.47
5
3.58
4.86
Total current assets
188
389
445
303
324
310
237
183
107
144
Property, plant and equipment
4.39
4.22
6.93
7.37
6.95
5.96
5.07
3.96
2.47
1.3
Lease right-of-use assets
25.4
22.5
19.4
15.9
12.2
8.14
3.4
Goodwill
0.95
0.95
0.95
0.95
0.95
0.95
0.95
0.95
0.95
0.95
Other non-current assets
2.97
1.36
1.38
2.02
2.17
0.9
0.03
0.08
0.07
0.03
Total assets
199
398
457
341
359
339
261
202
121
152
Accounts payable
6.6
4.21
5.13
4.16
3
2.82
2.81
1.46
1.09
1.3
Accrued liabilities
8.82
16.4
26.7
30.1
23.1
34.2
24.5
17.6
12.3
14.2
Deferred revenue
20.3
40.6
52.7
51.4
42.1
40.8
121
132
67.2
26.9
Total current liabilities
35.8
61.1
97.9
85.6
68.1
77.9
153
156
85.8
46.6
Lease liabilities
24.9
21.7
18.1
14
9.39
4.24
0
Other non-current liabilities
0.57
1.9
3.05
0.85
0
3.89
4.12
4.35
Total liabilities
121
328
326
290
366
340
347
249
121
52.6
Paid-in capital
255
289
446
468
500
623
637
676
691
811
Retained earnings
-176
-219
-315
-443
-508
-624
-723
-723
-692
-712
Other comprehensive income
-0.03
-0.09
-0.09
0.06
-0.05
-0.24
0.01
0.1
0.03
0.11
Shareholders' equity
78.5
69.9
136
25.5
-7.77
-0.46
-85.8
-47.4
-0.46
99
Total equity
78.5
69.9
136
25.5
-7.77
-0.46
-85.8
-47.4
-0.46
99
Total liabilities and equity
199
398
457
341
359
339
261
202
121
152
Shares outstanding
36.5
38.5
45.1
45.5
48.3
65.4
66.2
67.3
80.1
170
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-58.9
-43.1
-84.6
-133
-64.8
-116
-99.3
-0.57
31.9
-17.4
Depreciation and amortization
1.73
1.65
1.88
2.5
2.4
2.6
2.3
2
1.6
1.2
Stock-based compensation
10.1
11.3
16.9
19.1
14.8
13.2
13.1
8.56
7.67
6.3
Deferred income tax
-0.02
-0.51
-0.04
0
0
0
0
0
Change in receivables
-1.79
-7.98
10
0.08
-0.79
0.01
-35.2
32.6
0.33
1.09
Change in payables
1.77
-2.44
0.26
-0.37
-0.86
-0.14
0.07
-1.43
-0.3
0.22
Cash from operations
-2.03
170
-75.5
-140
5.26
-119
-111
-56
-86.2
-75.6
Capital expenditures
-2.18
-1.56
-3.79
-3.5
-2.31
-1.61
-1.74
-0.84
-0.31
-0.22
Purchases of investments
-122
-219
-205
-175
-199
-99.9
0
-425
-155
-193
Sales and maturities of investments
170
99
214
258
183
124
Cash from investing
45.9
-121
5.93
79.7
-18.7
22.5
98.3
-151
99.7
-59.7
Stock issued
20
135
0
11.3
108
0
6.91
110
Cash from financing
1
23.8
140
1.63
16.9
110
0.65
30.2
7.52
110
Net change in cash
44.8
72.9
70
-59.2
3.43
13.7
-11.9
-176
21
-24.9
Free cash flow
-4.21
169
-79.3
-144
2.95
-121
-113
-56.9
-86.5
-75.8
Income taxes paid
13.1
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.70 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-476.2%
Operating income / revenue.
Pre-tax margin
-434.0%
Pre-tax income / revenue.
Net margin
-435.2%
Net income / revenue.
FCF margin
-450.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-450.3%
Cash from operations / revenue.
Return on equity (ROE)
-26.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-20.9%
Net income / average total assets.
Return on invested capital (ROIC)
-24.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
400.9%
Research and development expense / revenue.
Stock-based pay / revenue
55.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.4%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-44.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
12.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
2.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y
-189.5%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-179.6%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-154.5%
Net income vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
25.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-16.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-15.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
62.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
28.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
24.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.36x
Current assets / current liabilities.
Quick ratio
9.23x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.29x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.08
Revenue / diluted weighted shares.
FCF per share
-$0.38
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.38
Cash from operations / diluted weighted shares.
Book value per share
$1.38
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
32.1x
Market cap / revenue.
P/B
1.95x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.95x
Market cap / tangible book value, when positive.
EV/Sales
14.1x
Enterprise value / revenue.
FCF yield
-14.0%
Free cash flow / market cap.
Earnings yield
-13.5%
Net income / market cap (the inverse of P/E).
What was CytomX Therapeutics, Inc.'s revenue in fiscal 2025?
CytomX Therapeutics, Inc. reported revenue of $76.2M for fiscal 2025, 44.8% lower than the year before.
Was CytomX Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $17.4M.
How much free cash flow did CytomX Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $75.6M minus capital expenditures of $220.0K left free cash flow of -$75.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.